Pharmaceutical manufacturing is undergoing a major structural shift as companies like GSK, Bristol Myers Squibb, and Sanofi sell production facilities to CDMOs. Reported in May 2026, this wave of asset transfers reflects rising GMP compliance costs, onshoring pressure, and demand
